PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Molocea, C.-E. ; Tsokanos, F.-F. ; Herzig, S.

Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies.

Curr. Opin. Pharmacol. 53, 101-116 (2020)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
Obesity and cancer cachexia are diseases at opposite ends of the BMI. However, despite the apparent dichotomy, these pathologies share some common underlying mechanisms that lead to profound metabolic perturbations. Insulin resistance, adipose tissue lipolysis, skeletal muscle atrophy and systemic inflammation are key players in both diseases. Several strategies for pharmacological treatments have been employed in obesity and cancer cachexia but demonstrated only limited effects. Therefore, there is still a need to develop novel, more effective strategies. In this review we summarize existing therapies and discuss potential novel strategies that could arise by bridging common aspects between obesity and cachexia. We discuss the potential role of macrophage manipulation and the modulation of inflammation by targeting Nuclear Receptors (NRs) as potential novel therapeutic strategies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.807
1.233
4
4
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Keywords Necrosis-factor-alpha; Adipose-tissue Inflammation; Type-2 Diabetes-mellitus; Cell Lung-cancer; Double-blind; Skeletal-muscle; Tnf-alpha; Insulin Sensitivity; Ppar-gamma; Antibody Treatment
Language
Publication Year 2020
HGF-reported in Year 2020
ISSN (print) / ISBN 1471-4892
e-ISSN 1471-4973
Journal Current opinion in pharmacology
Quellenangaben Volume: 53, Issue: , Pages: 101-116 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place London
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Cancer (IDC)
POF-Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-501900-251
G-502500-001
G-501900-253
Grants Deutsche Forschungsgemeinschaft DFG
Helmholtz Future Topic Aging and Metabolic Reprogramming (AMPro)
DOI 10.1016/j.coph.2020.07.006
WOS ID WOS:000591504200014
Scopus ID 85090047984
PubMed ID 32871469
Erfassungsdatum 2020-10-26
[➜Report correction]